Triapine
Modify Date: 2024-01-03 13:05:36
Triapine structure
|
Common Name | Triapine | ||
|---|---|---|---|---|
| CAS Number | 143621-35-6 | Molecular Weight | 195.245 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 436.0±55.0 °C at 760 mmHg | |
| Molecular Formula | C7H9N5S | Melting Point | 234°C(lit.) | |
| MSDS | Chinese USA | Flash Point | 217.5±31.5 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of TriapineTriapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer. |
| Name | 2-((3-Aminopyridin-2-yl)methylene)hydrazinecarbothioamide |
|---|---|
| Synonym | More Synonyms |
| Description | Triapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR), and is a potent radiosensitizer. |
|---|---|
| Related Catalog | |
| Target |
Ribonucleotide reductase (RR)[1] |
| In Vitro | Triapine is a potent derivative of α-heterocyclic carboxaldehyde thiosemicarbazone (HCT) that inhibits hRRM2 and p53R2 isoforms of the M2 subunit[1]. Triapine is thought to inhibit ribonucleotide reductase through its preformed iron chelate, rather than directly by removing iron from the active site. In cells containing less topoisomerase IIα fewer DNA strand breaks will be produced, and thus topoisomerase II poisons will be less inhibitory in the K/VP.5 cell line. The IC50s for Dp44mT growth inhibition are 48±9 nM and 60±12 nM, for K562 and K/VP.5 cells, respectively. The IC50s for Triapine growth inhibition are 476±39 nM and 661±69 nM for K562 and K/VP.5 cells, respectively[2]. PKIH and DpT Fe chelators show high antiproliferative activity against a range of tumor cell lines. Dp44mT shows the greatest antitumor efficacy with an IC50 that ranged from 0.005 to 0.4 μM. The average IC50 of Dp44mT over 28 cell types is 0.03±0.01 μM, which is significantly lower than that of Triapine (average IC50: 1.41±0.37 μM)[3]. |
| In Vivo | Triapine causes a significant increase (1.7-fold) in splenic weight when expressed as a percentage of total body weight (1.02±0.06%; n=25) compared with control mice (0.6±0.03%; n=27). In the long-term group, a significant increase in heart weight is observed after Dp44mT (0.4 mg/kg per day) (0.8±0.06%; n=4) compared with control mice (0.5±0.01%; n=6). A significant decrease in the expression of Ndrg1, TfR1, and VEGF1 in the liver is noted for Dp44mT- and Triapine (12 mg/kg per day)-treated animals. The decreased expression could be related to the increased liver Fe in both Dp44mT- and Triapine-treated mice[3]. |
| Cell Assay | An MTT assay is used to determine cell growth inhibition of CHO cells. Human leukemia K562 cells and K/VP.5 cells (a 26-fold etoposide-resistant K562-derived sub-line with decreased levels of topoisomerase IIα mRNA and protein) are maintained as suspension cultures in "MEM (Minimal Essential Medium Alpha, Invitrogen) containing 10% fetal calf serum (FCS). For growth inhibition assays, K562 and K/VP.5 cells are plated at a concentration of 1.5×105 cell/mL, and incubated 5 d with various concentrations of Dp44mT, Triapine or vehicle (DMSO) for 48 h, after which cells are counted on a model ZBF Coulter counter. The IC50 growth inhibitory concentration for each cell line is calculated from a non-linear least-squares fit to a 2-parameter logistic equation[2]. |
| Animal Admin | Mice[3] Female BALB/c nu/nu mice are used at 8-10 weeks of age. Tumor cells in culture are harvested, and 107 cells are suspended in Matrigel and injected s.c. into the right flanks of mice. After engraftment, tumor size is measured by Vernier calipers. Tumor volumes (in cubic millimeters) are calculated. When tumor volumes reached 120 mm3, i.v. treatment began (day 0). Chelators (e.g., Triapine) are dissolved in 15% propylene glycol in 0.9% saline and injected i.v. over 5 consecutive days per week for up to 7 weeks. Control mice are treated with vehicle alone. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 436.0±55.0 °C at 760 mmHg |
| Melting Point | 234°C(lit.) |
| Molecular Formula | C7H9N5S |
| Molecular Weight | 195.245 |
| Flash Point | 217.5±31.5 °C |
| Exact Mass | 195.057861 |
| PSA | 125.95000 |
| LogP | 0.98 |
| Appearance of Characters | white to light brown |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.720 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: soluble10Meq/mL, clear |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H315-H319-H335 |
| Precautionary Statements | P261-P301 + P310-P305 + P351 + P338 |
| Hazard Codes | Xn |
| Risk Phrases | 22-36/37/38 |
| Safety Phrases | 26 |
| RIDADR | UN 2811 6.1 / PGIII |
| HS Code | 2933990090 |
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Trypanotoxic activity of thiosemicarbazone iron chelators.
Exp. Parasitol. 150 , 7-12, (2015) Only a few drugs are available for treating sleeping sickness and nagana disease; parasitic infections caused by protozoans of the genus Trypanosoma in sub-Saharan Africa. There is an urgent need for ... |
|
|
Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.
Antioxid. Redox Signal. 18(8) , 956-72, (2013) Despite advances made in the treatment of cancer, a significant number of patients succumb to this disease every year. Hence, there is a great need to develop new anticancer agents.Emerging data show ... |
|
|
Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.
Cancer Res. 75 , 2863-74, (2015) Generalized strategies to improve breast cancer treatment remain of interest to develop. In this study, we offer preclinical evidence of an important metabolic mechanism underlying the antitumor activ... |
| 2-[(3-Amino-2-pyridinyl)methylene]hydrazinecarbothioamide |
| 2-[(3-Aminopyridin-2-yl)methylene]hydrazinecarbothioamide |
| 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP PAN-811 |
| (2E)-2-[(3-Amino-2-pyridinyl)methylene]hydrazinecarbothioamide |
| Hydrazinecarbothioamide, 2-[(3-amino-2-pyridinyl)methylene]- |